AFT Pharmaceuticals Ltd. (AU:AFP)
ASX:AFP
Total Valuation
AFT Pharmaceuticals Ltd. has a market cap or net worth of AU$342.86M. The enterprise value is AU$459.14M.
Market CapAU$342.86M
Enterprise ValueAU$459.14M
Share Statistics
AFT Pharmaceuticals Ltd. has 104,866,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,866,260
Owned by Insiders69.92%
Owned by Institutions―
Financial Efficiency
AFT Pharmaceuticals Ltd.’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 9.80%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)9.80%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee2.32M
Profits Per Employee133.91K
Employee Count110
Asset Turnover1.17
Inventory Turnover1.95
Valuation Ratios
The current PE Ratio of AFT Pharmaceuticals Ltd. is 28.0. AFT Pharmaceuticals Ltd.’s PEG ratio is 0.88.
PE Ratio28.0
PS Ratio1.38
PB Ratio3.19
Price to Fair Value3.19
Price to FCF-29.69
Price to Operating Cash Flow-35.07
PEG Ratio0.88
Income Statement
In the last 12 months, AFT Pharmaceuticals Ltd. had revenue of 254.71M and earned 14.73M in profits. Earnings per share was 0.14.
Revenue254.71M
Gross Profit110.55M
Operating Income24.86M
Pretax Income21.87M
Net Income14.73M
EBITDA28.55M
Earnings Per Share (EPS)0.14
Cash Flow
In the last 12 months, operating cash flow was -11.75M and capital expenditures -116.00K, giving a free cash flow of -11.87M billion.
Operating Cash Flow-11.75M
Free Cash Flow-11.87M
Free Cash Flow per Share-0.11
Dividends & Yields
AFT Pharmaceuticals Ltd. pays an annual dividend of AU$0.017, resulting in a dividend yield of 0.54%
Dividend Per ShareAU$0.017
Dividend Yield0.54%
Payout Ratio11.34%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.31
52-Week Price Change24.71%
50-Day Moving Average2.99
200-Day Moving Average2.85
Relative Strength Index (RSI)63.67
Average Volume (3m)2.52K
Important Dates
AFT Pharmaceuticals Ltd. upcoming earnings date is Nov 19, 2026, After Close (Confirmed).
Last Earnings DateMay 20, 2026
Next Earnings DateNov 19, 2026
Ex-Dividend Date―
Financial Position
AFT Pharmaceuticals Ltd. as a current ratio of 2.24, with Debt / Equity ratio of 49.06%
Current Ratio2.24
Quick Ratio1.12
Debt to Market Cap0.15
Net Debt to EBITDA1.54
Interest Coverage Ratio9.98
Taxes
In the past 12 months, AFT Pharmaceuticals Ltd. has paid 7.79M in taxes.
Income Tax7.79M
Effective Tax Rate0.36
Enterprise Valuation
AFT Pharmaceuticals Ltd. EV to EBITDA ratio is 13.88, with an EV/FCF ratio of -33.39.
EV to Sales1.56
EV to EBITDA13.88
EV to Free Cash Flow-33.39
EV to Operating Cash Flow-33.72
Balance Sheet
AFT Pharmaceuticals Ltd. has AU$10.24M in cash and marketable securities with AU$54.11M in debt, giving a net cash position of -AU$43.87M billion.
Cash & Marketable SecuritiesAU$10.24M
Total DebtAU$54.11M
Net Cash-AU$43.87M
Net Cash Per Share-AU$0.42
Tangible Book Value Per ShareAU$0.43
Margins
Gross margin is 43.40%, with operating margin of 9.76%, and net profit margin of 5.78%.
Gross Margin43.40%
Operating Margin9.76%
Pretax Margin8.59%
Net Profit Margin5.78%
EBITDA Margin11.21%
EBIT Margin9.76%
Analyst Forecast
The average price target for AFT Pharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast19.26%
EPS Growth Forecast19.01%